Home
by admin

Peloton Minerals Clarifies Assay Results

London, Ontario — March 13, 2026 — Leads & Copy — Peloton Minerals Corporation (CSE: PMC; OTCQB: PMCCF) has issued a clarification regarding certain assay results previously reported in a news release dated January 28, 2026.

An internal review of analytical data and disclosure revealed that the cesium (Cs) assays reported were made in error. The assays attributed to cesium (Cs) were, in fact, the cerium (Ce) assays. Actual cesium (Cs) assays range from 1 part per million (“ppm”) to 70 ppm, averaging 16.7 ppm across all four drill holes.

The clarification pertains solely to the inadvertent reversal of the cerium and cesium assays in the original disclosure. Rubidium (Rb) and lithium (Li) values reported in the original release were accurately transcribed and remain unchanged.

Peloton Minerals has reviewed its disclosure procedures and will implement additional verification steps to ensure consistency between laboratory analytical reports and public disclosure.

Peloton Minerals Corporation is a reporting issuer in good standing in British Columbia and Ontario. Its common shares are listed on the CSE (Symbol: PMC) and trade in the U.S. on the OTC QB (Symbol: PMCCF). There are 152,567,062 common shares issued and outstanding.

Peloton’s exploration portfolio includes the North Elko Lithium Project in northeastern Nevada, prospective for lithium, uranium, critical and rare earth minerals, as well the Golden Trail and Independence Valley Carlin style gold projects in northeastern Nevada, and a non-controlling interest in a copper porphyry project near Butte, Montana.

Richard C. Capps, PhD, the Company’s Senior Geologist and a Director, is the qualified person under NI 43-101 who approved the technical information in this release.

CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Source: Peloton Minerals Corporation

LeadsAndCopy

Share this story:

TwitterFacebookLinkedInEmail
×

Welcome!

BiotechReporter.news is a Leads & Copy Publication

Leads & Copy is a Media “news tip” source, providing Industry Reporters story Leads, written as Publishable CP-style Copy.

By Subscribing you will receive Daily Biotech Story Leads via email 10:30 am Mon-Fri.